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A B S T R A C T
Optimal candidates for VNS as a treatment for refractory epilepsy have not been identiﬁed. In this
retrospective two-center study, we used the Engel classiﬁcation for evaluating seizure outcome, and
tried to identify predictive factors for outcome by means of subgroup analysis. The medical records of
patients who have been treated with VNS for at least one year at Dartmouth–Hitchcock Medical Center
and Ghent University Hospital were evaluated. Seizure frequency outcomewas assessed using the Engel
classiﬁcation for the study population as a whole, and for patient subgroups with regard to mental
functioning, seizure type, predisposing factors for developing epilepsy, age at time of VNS implantation
and epilepsy duration. 189 patients (102M/87F) were included in the study (mean FU: 41 months). 6%
had a class I outcome (seizure-free), 13% a class II outcome (almost seizure-free), 49% a class III outcome
(worthwhile improvement) and 32% had a class IV outcome (no improvement). When patients were
divided into speciﬁc subgroups, a statistically signiﬁcant better outcomewas found patientswith normal
mental functioning (p = 0.029). In our series, results for VNS are clearly inferior to resective surgery, but
comparable to other treatmentmodalities for refractory epilepsy. With combined class I and II outcomes
around 20%, and another 50% of patients having worthwhile improvement, VNS is a viable alternative
when resective surgery is not feasible.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Electrical stimulation of the tenth cranial nerve or vagus nerve
stimulation (VNS) is an extracranial form of neurostimulation that
was developed more than 20 years ago.1 In the past decade it has
become a valuable therapeutic option for patients with refractory
epilepsy and it is currently available in epilepsy centersworldwide.
It is indicated in patients with refractory epilepsy who are
unsuitable candidates for epilepsy surgery or who have had
insufﬁcient beneﬁt from such a treatment.2 As for many anti-
epileptic treatments, clinical application of VNS preceded the
elucidation of its mechanism of action, which is unknown up to
date. The ﬁrst clinical studies of VNS included almost exclusively
patients with focal seizures.3 In the following years, the efﬁcacy of
VNS in other seizure types and epilepsy syndromes was* Corresponding author at: Reference Center for Refractory Epilepsy, Department
of Neurology 1K12IA, Ghent University Hospital, De Pintelaan 185, 9000 Ghent,
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doi:10.1016/j.seizure.2011.01.002assessed.4,5 These studies reported efﬁcacy results comparable
to those seen in focal epilepsy. The current consensus is that 1/3 of
patients have considerable improvement in seizure control with a
seizure frequency reduction of at least 50%, and 1/3 of patients
experience a worthwhile reduction of seizure frequency between
30 and 50%. Long-term follow-up studies show improved seizure
control over time. However, even after long-term treatment, up to
25% of patients do not experience any positive effect of VNS.2 These
results are similar to the results of anti-epileptic drug trials in
patients with refractory epilepsy. Those, as well as the VNS studies,
are usually reported so that the principle seizure outcome is the
‘‘responder rate’’, which is deﬁned as the proportion of patients
who have a 50% or greater reduction in seizure frequency. Seizure-
free rates are seldom reported, and when reported, usually less
than 5%.6
In contrast, most trials and case series in epilepsy surgery have
used the Engel classiﬁcation. The Engel classiﬁcation scale was
proposed by Jerome Engel as a standard outcome scale after
resective epilepsy surgery (Table 1).7 This scale divides outcomes
into one of four classes. A patient free of disabling seizures is
classiﬁed as class I. Patients with no seizures, simple partial non-
disabling seizures only, and/or a seizure free period of eightvier Ltd. All rights reserved.
Table 1
Classiﬁcation of postoperative outcome (Engel classiﬁcation).6
Class I No disabling seizures
A Completely seizure-free since surgery
B Non-disabling simple partial seizures only
C Some disabling seizures after surgery, but free of disabling seizures
for at least 2 years
D Generalized convulsion with antiepileptic drug withdrawal only
Class II Rare disabling seizures
A Initially free of disabling seizures but has rare disabling seizures
now
B Rare disabling seizures since surgery
C More than rare disabling seizures since surgery, but rare seizures
for at least 2 years
D Nocturnal seizures only
Class III Worthwhile improvement
A Worthwhile seizure reduction
B Prolonged seizure-free intervals but less than 2 years
Class IV No worthwhile improvement
A Signiﬁcant seizure reduction
B No appreciable change in seizure frequency
C Seizures are more frequent or worse
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category. A class II outcome is one in which the patient has rare
seizures at a frequency of three or less per year. Class III outcome
corresponds to a ‘‘worthwhile’’ result occurring through a
reduction either in seizure frequency or seizure intensity that
improves the patient’s quality of life. A patient is assigned to class
IV when seizure frequency is not reduced, or reduced only to such
limited extent that it does not improve day-to-day functioning. A
major advantage of using the Engel classiﬁcation is that not only
seizure frequency is taken into account, but also the impact of
seizures on quality of life. Most surgical series are reporting class I
outcomes in 50–65% of patients, and combined class I and II
outcomes around 80%.8
In this retrospective two-center study, 191 VNS patients at
Dartmouth–Hitchcock Medical Center and Ghent University
Hospital were evaluated using the Engel classiﬁcation scale. VNS
was offered here to patients who were not candidates for resective
surgery, but we estimated that the use of a single scale for
comparison of outcomes would be valuable. Also, since VNS is a
surgical treatment, we estimated that in order to judge its efﬁcacy
we should subject it to themore stringent Engel criteria rather than
the more lax standards of drug studies. Outcomes in the entire
patient population were determined, as well as the outcomes in
several patient subgroups, to identify predictive factors for VNS
response. Characteristics examined were mental functioning,
seizure type, age at VNS implantation, predisposing factors for
epilepsy, and epilepsy duration.
2. Methods
2.1. Patient population
Two epilepsy centers participated in this open retrospective
study: Dartmouth–Hitchcock Medical Center, Lebanon, New
Hampshire, USA and Ghent University Hospital, Gent, Belgium.
All patients included in the study underwent presurgical evalua-
tion including long-term video-EEG monitoring and MRI with an
epilepsy protocol that included additional coronal temporal views
and T2 weighted or FLAIR sequences. All patients were for various
reasons considered to be unsuitable candidates for resective
surgery, and were subsequently treated with VNS. Patients with a
post-implantation follow-up of at least 12 months were included
in this analysis. For each patient, data on age at seizure onset, types
of seizures, age at time of implantation, seizure frequency beforeand after VNS treatment, level of mental functioning, VNS
stimulation parameters, number of antiepileptic drugs (AEDs)
taken before implantation and at maximum follow-up, and
predisposing factors for epilepsy, were collected from the patient’s
medical records. Approval of the Ethical Committee of Ghent
University Hospital and Dartmouth–HitchcockMedical Center was
obtained prior to the start of the study.
2.2. Seizure outcome using the Engel classiﬁcation
Each patient included in this study was assigned to an outcome
class, using the Engel classiﬁcation. This assessment was done at
latest follow-upby a thorough reviewof the patients’ seizure diaries
and medical ﬁles, and by taking into account changes in seizure
frequency, seizure intensity, and the impact of these changes on the
patients’ quality of life. Outcome class was determined principally
by seizure frequency, but in patients with mental retardation,
caregivers’ assessment of quality of life was taken into account in
deciding between class III and class IV outcomes. Since the Engel
classiﬁcation deﬁnes class III as ‘‘worthwhile improvement’’ we felt
justiﬁed in taking factors other than seizure frequency into account
for class III, but not for classes I and II.
2.3. Seizure outcome in different patient subgroups
Patients were divided into two groups with regard to mental
functioning, using a full scale IQ score (FSIQ) obtained during the
presurgical neuropsychological examination. Patients with a FSIQ
of 70 or more were placed in the group of ‘‘normal mental
functioning’’ and those with scores of 69 or less were classiﬁed as
having ‘‘impaired mental functioning’’. Some patients were so
severely retarded that they could not be tested in a reliable way
and were assigned to the ‘‘impaired mental functioning’’ group for
obvious reasons.
Another analysis divided patients into three groups based on
seizure type. One group contained patients with only focal
seizures. A second group contained patients with tonic clonic
seizures. Idiopathic and symptomatic epilepsies were not distin-
guished, and patients with focal seizures and occasional tonic
clonic seizures were also included in this group. A third group
contained patientswith other seizures types such as atonic or tonic
seizures, myoclonic seizures and absence seizures, often in
combination with tonic clonic seizures. This group contained a
large proportion of patients with Lennox–Gastaut syndrome.
Subgroup analysis was also done according to predisposing
factors for developing epilepsy. These factors included head
trauma preceding the onset of epilepsy, history of intracranial
infection, history of birth complications, and history of febrile
seizures. Patients were divided into groups with one of the above
risk factors, a group with more than one of the previously
mentioned risk factors or with other risk factors including brain
tumors and neuronal migration disorders, and a group with no
identiﬁable risk factors before epilepsy onset.
Age was looked at in two ways. First, patients were divided
according to their age at the time of VNS implantation. For this
purpose, they were divided into 3 age groups with 20 year
intervals. Second, patients were divided into 2 groups depending
on the duration of their epilepsy at the time of VNS implantation.
One group contained patients with an epilepsy duration of 0–10
years, the other group contained patients with an epilepsy
duration of more than 10 years.
2.4. Statistics
Statistical analysis was performed bymeans of the independent
samples T-test and Chi square test where indicated. To simplify the
Table 3
Comparison of subgroups regarding seizure type.
Class I and II Class III Class IV
Partial seizures N=53 14 (26%) 21 (40%) 18 (34%)
Tonic clonic seizures N=95 18 (19%) 53 (56%) 24 (25%)
Multiple seizure types N=41 4 (10%) 18 (44%) 19 (46%)
Outcomes following the Engel classiﬁcation are given in subgroups regarding
seizure type.
Table 4
Comparison of subgroups regarding predisposing factors for epilepsy.
Class I and II Class III Class IV
Head trauma N=25 10 (40%) 11 (44%) 4 (16%)
Intracranial infection N=15 4 (27%) 8 (53%) 3 (20%)
Birth complication N=20 1 (5%) 14 (70%) 5 (25%)
Febrile seizures N=13 2 (15%) 10 (77%) 1 (8%)
Multiple/other N=46 8 (17.5%) 18 (39%) 20 (43.5%)
No/unknown N=70 11 (16%) 31 (44%) 28 (40%)
Outcomes following the Engel classiﬁcation are given in subgroups regarding
predisposing factors for epilepsy.
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189 Patients (102M/87F) were included in the study (89/189
Ghent University Hospital, 100/189 Dartmouth–Hitchcock Medi-
cal Center). Mean follow-up was 41 months (range 12–144
months). Mean age at time of VNS implantation was 30 years
(range 2–60 years) and mean duration of epilepsy was 21 years
(range 1–60 years). The mean number of AEDs remained
unchanged before implantation and at maximum follow-up (3,
range: 0–5).
3.2. Seizure outcome using the Engel classiﬁcation
11/189 (5.8%) Patients were assigned to a class I outcome, and
25/189 (13.2%) patients had class II outcomes. The class I and class
II groups were combined into a group representing very good
seizure outcome, thus making a total of 36 patients (19.0%).
Another 92 patients (48.7%) had a ‘‘worthwhile’’ improvement
with regard to seizure control and/or quality of life, and were
assigned class III outcomes. 61/189 Patients (32.3%) had no
improvement in their condition after VNS implantation and were
regarded as class IV outcomes.
3.3. Stimulation output
Mean stimulation output current at latest follow-up was
1.6 mA (range 0–3.5). In two patients, stimulation output current
was programmed to 0 mA after at least 12 months of VNS
treatment, due to lack of efﬁcacy. The combined class I and class II
groups were programmed to receive signiﬁcantly (p < 0.01,
independent samples T-test) lower stimulation output currents
(1.2 mA; range 0.25–2.5) when compared to the combined class III
and class IV groups (1.75 mA; range 0–3.5).
3.4. Seizure outcome in different patient subgroups
3.4.1. Mental functioning (Table 2)
When the outcome classiﬁcation of the 117 patients with
normal mental functioning was compared with the outcome of the
72 patients with mental impairment, a statistically signiﬁcant
better outcome was found in patients with normal mental
functioning (p = 0.029).
3.4.2. Seizure type (Table 3)
53/189 Patients had partial seizures without secondary
generalization. 14/53 (26%) showed a class I or II outcome. 95
Patients experienced primary or secondarily generalized tonic
clonic seizures. 18/95 (18.9%) had a class I or II outcome. 41
Patients had other seizures types. 4/41 (10%) had a class I or IITable 2
Comparison of subgroups regarding mental functioning.
Class I and II Class III Class IV
IQ70 N=117 28 (24%)* 59 (50%) 30 (26%)
IQ<70 N=72 8 (11%) 33 (46%) 31 (43%)
Outcomes following the Engel classiﬁcation are given in subgroups regarding
mental functioning.
* Statistical signiﬁcance (p<0.05, Chi square test).outcome. Seizure type did not affect seizure outcome after VNS in a
statistically signiﬁcant manner.
3.4.3. Predisposing factors for epilepsy (Table 4)
A total of 25/189 patients had experienced head trauma as sole
risk factor preceding the onset of their seizures. 10/25 (40%) had a
class I or II outcome. Of the 15/189 patients who had a history of
intracranial infection, 4/15 (27%) had a class I or II outcome. The
percentage of class I or II outcomes for the 20/189 patients with a
history of birth complication was 1/20 (5%). Of the 13/189 patients
with a history of febrile seizures, 2/13 (15%) had a class I or II
outcome. 46/189 Patients had a combination of the previously
deﬁned risk factors or had other risk factors predisposing them to
develop epilepsy. Of those patients, 8/46 (17.5%) had class I or II
outcomes. Finally, 70/189 patients had no or unknown risk factors
for seizures. 11/70 (16%) had a class I or II outcome. The differences
between the groups were not statistically signiﬁcant.
3.4.4. Age at time of VNS implantation (Table 5)
45/189 Patients were implanted at the age of 20 years or
younger and 13% of them had a class I or II outcome. 98/189
Patients had VNS between the ages of 21 and 40 years and 18% had
a class I or II outcome. VNS implantation at 41 years and older
yielded 26% class I and II outcomes. No statistically signiﬁcant
differences could be demonstrated.
3.4.5. Epilepsy duration (Table 6)
No statistical differences were found between the group with
epilepsy duration of less than 10 years and the groupwith epilepsy
duration of more than 10 years.
4. Discussion
In this study, VNS at Dartmouth–Hitchcock Medical Center and
Ghent University Hospital was shown to be an effective add-onTable 5
Comparison of subgroups regarding age at time of implantation.
Class I and II Class III Class IV
0–20 years N=45 6 (13%) 17 (38%) 22 (49%)
21–40 years N=98 18 (18%) 50 (51%) 30 (31%)
>41 years N=46 12 (26%) 25 (54%) 9 (20%)
Outcomes following the Engel classiﬁcation are given in subgroups regarding age at
time of implantation.
Table 6
Comparison of subgroups regarding epilepsy duration.
Class I and II Class III Class IV
0–10 years N=46 7 (15%) 21 (46%) 18 (39%)
>10 years N=143 29 (20%) 71 (50%) 43 (30%)
Outcomes following the Engel classiﬁcation are given in subgroups regarding
epilepsy duration.
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very good (class I and II) outcome with VNS and 48.7% had a
worthwhile (class III) improvement of their condition, when using
the Engel classiﬁcation for seizure outcome after epilepsy surgery.
Although important differences exist between VNS therapy and
resective surgery, using the same classiﬁcation for seizure outcome
has some advantages. In most studies analyzing VNS efﬁcacy and
trying to identify prognostic factors for seizure reduction, a >50%
seizure frequency reduction has been the primary outcome
measurement. But even in refractory epilepsy patients, achieving
seizure freedom is still the ultimate epilepsy care goal. The Engel
classiﬁcation iswell knowntoepileptologists, clearly identiﬁes those
whoare seizure freeoralmost seizure free, andtakes intoaccountnot
only seizure frequency, but also the impact of the seizures on daily
life. Moreover, this allows a comparison between VNS and resective
surgery, both of which are invasive epilepsy treatments.
In a previous publication, we demonstrated that VNS outcomes
in the Dartmouth–Hitchcock Medical Center and in the Ghent
University Hospital patient population using % seizure frequency
reduction as an outcome measure, were comparable with those
described in literature.9 One recent study by McHugh et al.
compared a new classiﬁcation system for VNS outcome with the
Engel classiﬁcation. 6/48 (12%) of the patients included in that
study were assigned to Engel classes I and II.10 However, the VNS
outcome classiﬁcation proposed byMcHugh et al. has ﬁve outcome
categories and is difﬁcult to compare with resective surgical
outcomes, and equally difﬁcult to compare with drug study
outcomes. We therefore believe that analyzing VNS outcome data
with both the Engel approach and the % seizure reduction approach
yields the best comparisons.
When the outcome of VNS presented in this study is compared
to the outcome of other epilepsy treatments in a refractory
population, the relatively small number of a very good outcome
becomes more acceptable. With regard to the use of antiepileptic
drugs (AEDs), one third to one half of newly treated epilepsy
patients are refractory to initial treatment. Of those, only 5–10%
will obtain seizure freedom with the use of additional AEDs, and
usually less than one half will have a 50% reduction in seizure
frequency with any new drug.6,11 This is true for both the older
drugs and the new generation of drugs, that despite having fewer
side effects, seem to have the same level of efﬁcacy.12 Of the one
third of patients who are medically refractory, perhaps half are
candidates for resective epilepsy surgery. For temporal lobe
surgery, outcomes are very good and in one study of 215 patients
by Salanova et al. a seizure-free rate of 89% was achieved.13 Long
term outcome studies are showing seizure-free rates of 60–70%
and combined Engel class I and II outcomes are around 80%.8 In
frontal lobe epilepsy surgery, Worrel et al. found an overall success
rate of 52%.14 In cases where other extra-temporal regions are
involved, surgery can be risky and yield rather poor results. One
example comes from a study by Aykut-Bingol et al. in which
seizure-freedom in patients who had surgery for occipital lobe
epilepsy, varied from 17 to 56%.15
Among patients with unresectable seizure foci, or those who
have failed resective surgery, options are limited. Additional drug
trials offer very low rates of seizure freedom, and most studies
report less than 50% of patients having a 50% reduction in seizurefrequency. Other surgical options such as callosotomy, subpial
transsections, and experimental surgical treatments such as deep
brain stimulation, offer no better results.16–18 In this context, VNS
results such as those reported here, with 18% very good outcomes
and another 49% showing worthwhile improvement, seem quite
attractive.
In our study there was a signiﬁcantly lower VNS output current
in the group of patients with class I and II seizure outcomes.
Similarly, Labar found that patients with better clinical outcomes
had their VNS programmed at a signiﬁcantly lower output current
than patients who had a poorer outcome. He also found that 13
patients who stayed on exactly the same VNS settings and AED
regimen, had a decline in seizure rate reduction from 36% after 3
months to 85% after 12 months of follow-up.19 This suggests that
VNS responders tend to respond quite early, which halts the
process of further ramping-up of the stimulation intensity by the
physician, and that there is not always the need to continuously
adjust stimulation settings for optimizing seizure outcome. Ideal
stimulation parameters may be different for each individual, but
this has yet to be studied in randomized prospective studies with
different stimulation paradigms.
When it comes to the identiﬁcation of VNS responders, large
patient groups have been examined retrospectively, but identiﬁ-
cation of subgroups most likely to beneﬁt, prior to implantation,
seems one of the most difﬁcult issues in VNS treatment. One study
by Janszky et al. in 47 patients found that the absence of bilateral
interictal epileptiform discharges was associated with a statisti-
cally signiﬁcant increase in the likelihood of a seizure-free
outcome after VNS.20 In our study we used the Engel classiﬁcation
to identify predictive factors for seizure outcome. A signiﬁcantly
larger proportion of patients with normal intelligence had a class I
or II outcome. Despite the smaller chance of highly successful
outcomes, one might still recommend VNS for mentally impaired
patients because of the 50% chance for a class III outcome in
addition to improvement in their mood and overall condition.21
Since the subpopulations were small, it was difﬁcult to prove
statistical signiﬁcance for the other subgroups. However, future
prospective studies should target speciﬁc subpopulations based
upon their unique characteristics. In such trials one will need to
look not only at rates of seizure control but also at improvement in
quality of life using validated scales.
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